Fujii Yasuhiko
Affiliate Master
Yamaguchi University
Comparative Study with CHOP-Pepleo and COP-Pepleo Combunation Chemotherapy for Non-Hodgkin's Lymphoma
The bulletin of the Yamaguchi Medical School Volume 36 Issue 1-2
Page 21-27
published_at 1989-06
Title
Comparative Study with CHOP-Pepleo and COP-Pepleo Combunation Chemotherapy for Non-Hodgkin's Lymphoma
Creators
Tanaka Masahisa
Creators
Azuno Yoichi
Creators
Yoshizaki Yoshiki
Creators
Hatao Katsuhiro
Creators
Okubo Masashi
Creators
Inoue Yasushi
Creators
Matsutani Akira
Creators
Yaga Ken
Creators
Fujii Shinya
Creators
Ishida Yoji
Creators
Kaku Kohei
Creators
Matsumura Shigeichi
Creators
Kaneko Toshio
Creators
Shinohara Kenji
Creators
Hiroshige Yukio
Creators
Matsumoto Noboru
Source Identifiers
Creator Keywords
Non-Hodgkin's Lymphoma
Chemotherapy
CHOP-Pepleo
COP-Pepleo
Combination chemotherapy with CHOP-Pepleo regimen (cyclophosphamide, adriamycin, vincristine, prednisolone, and pepleomycin), or COP-Pepleo refimen (cyclophosphamide, vincristine, prednisolone, and pepleomycin), was used as a remission induction therapy for patients with mostly advanced non-Hodgkin's lymphomas. Among 23 patients treated with CHOP-Pepleo or CHOP without Pepleo (5 patients), 57% achieved complete remission with 78% overall response (complete remission plus partisl remission). Among 12 patients treated with COP-Pepleo, 50% achieved complete remissions with 83% overall response. No significant difference was odserved in response rates between two groups. Median follow-up durations ware 14 months for CHOP-People and 16 months for COP-Pepleo and 4 patients (67%) treated with COP-Pepleo relapsed within 20 months after achieving complete remission. Relapse-free survival rates at 4 years ware 54% for CHOP-Pepleo and 34% for COP-Pepleo. Each survival curve in the patients treated with CHOP-Pepleo or COP-Pepleo showed a plateau after 24 months. Though the addition of adriamycin did not improve complete remission rate significantly as a whole, the complete remission rate in stage Ⅳ , overall survival and relapse-free survival ware favorably inproved by the addition of adriamycin. Further study will be needed to assess the effect of adriamycin on response and survival in patients eith non-Hodgkin's lymphomas.
Languages
eng
Resource Type
departmental bulletin paper
Publishers
Yamaguchi University Graduate School of Medicine
Date Issued
1989-06
File Version
Version of Record
Access Rights
open access
Relations
[ISSN]0513-1812
[NCID]AA00594272
Schools
医学部